Asvini D. Fernando

Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial

Shibadas Biswal, Charissa Borja-Tabora, Luis Martinez Vargas et al. · The Lancet · 2020 · 237 citations

Vaccination, Vaccine Safety, Pediatrics +5

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)

Luis Rivera, Shibadas Biswal, Xavier Sáez‐Llorens et al. · Clinical Infectious Diseases · 2021 · 226 citations · Full text

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

Vianney Tricou, Delia Yu, Humberto Reynales et al. · The Lancet Global Health · 2024 · 189 citations · Full text

Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination

Eduardo López‐Medina, Shibadas Biswal, Xavier Sáez‐Llorens et al. · The Journal of Infectious Diseases · 2020 · 102 citations · Full text

Evidence for Better Lives Study: a comparative birth-cohort study on child exposure to violence and other adversities in eight low- and middle-income countries - foundational research (study protocol)

Sara Valdebenito, Aja Louise Murray, Claire Hughes et al. · BMJ Open · 2020 · 31 citations · Full text